

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(Rs. in Lakhs)

	Particulars	3 months ended 31.12.2025	Preceding 3 months ended 30.09.2025	Corresponding 3 months ended 31.12.2024	9 months ended 31.12.2025	9 months ended 31.12.2024	Year ended 31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	104126	97994	94942	282637	277484	374921
2	Other income	3212	3357	3507	10941	10525	14593
3	Total Income (1+2)	107338	101351	98449	293578	288009	389514
	Expenses						
	(a) Cost of materials consumed	7990	11513	9748	32309	38467	49990
	(b) Purchases of stock-in-trade	21727	23272	16423	68205	55371	84511
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	6665	768	9745	192	10054	4585
	(d) Employee benefits expense	15188	13805	12474	44250	42673	57970
	(e) Finance costs	119	51	9	212	73	131
	(f) Depreciation and amortisation expense	2032	1743	1880	5327	5207	6679
	(g) Other expenses	15422	15063	17360	41854	46502	60129
4	Total expenses	69143	66215	67639	192349	198347	263995
5	Profit before exceptional items and tax (3-4)	38195	35136	30810	101229	89662	125519
6	Exceptional items [credit] (Refer Note 2)	1798	264	-	2062	469	469
7	Profit before tax (5+6)	39993	35400	30810	103291	90131	125988
8	Tax expense						
	(a) Current tax	10226	9607	7349	27228	23581	32596
	(b) Deferred tax	205	44	473	251	79	634
9	Profit for the period/year (7-8)	29562	25749	22988	75812	66471	92758

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025


(Rs. in Lakhs)

	Particulars	3 months ended 31.12.2025	Preceding 3 months ended 30.09.2025	Corresponding 3 months ended 31.12.2024	9 months ended 31.12.2025	9 months ended 31.12.2024	Year ended 31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss	829	-	157	829	157	(355)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(209)	-	(39)	(209)	(39)	89
11	Total comprehensive income for the period (9+10)	30182	25749	23106	76432	66589	92492
12	Total comprehensive income for the period attributable to owners of the Group	30182	25749	23106	76432	66589	92492
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941	16941	16941
	Other equity						178190
	Earnings per share (EPS) (of Rs. 10 each)						
	Basic and diluted EPS before Exceptional items (Rs.)	16.54	15.07	13.57	43.71	39.00	54.52
	Basic and diluted EPS after Exceptional items (Rs.)	17.45	15.20	13.57	44.75	39.24	54.76
Not Annualised							

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 09th February 2026. The Statutory auditors have carried out a limited review of the consolidated financial results for the quarter and nine months ended 31st December 2025.
2. Exceptional items pertaining to the period / year :
 - i) Exceptional items credit for the period ended 31st December 2025 includes Rs. 264 lakhs on account of profit on sale of surplus residential properties and Rs 1798 lakhs on account of sale of non operational land site.
 - ii) Exceptional item credit for the year ended 31st March 2025 of Rs.469 lakhs is on account of profit on sale of surplus residential properties.
3. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations.
The Group has assessed and disclosed the incremental impact of these changes on the basis of actuarial valuation report. This has resulted in an increase of Rs. 1182 lakhs in Employee Benefits expense for the quarter and nine months ended December 31, 2025. The incremental impact primarily arises due to change in wage definition.
The Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
4. The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346

09th February, 2026